Please login to the form below

Not currently logged in
Email:
Password:

EUSA Pharma appoints Rolf Hoffmann to its board

He most recently worked at Amgen for over a decade

Roff HoffmannOncology-focused pharmaceutical group EUSA Pharma has added to its board of directors in the form of Rolf Hoffman.

Hoffman, who is currently chairman of Biotest and sits on the board of directors of Genmab, brings over 30 years’ pharmaceutical experience to his new position having served in a number of senior roles in the industry.

He most recently spent 12 years with Amgen as its senior vice president of commercial operations, US and prior to that, he worked for SVP.

Hoffman said: “I have watched EUSA Pharma’s remarkable progress in the three years since it was founded, and am delighted to now help the company achieve its ambitious plans.”

His new role will see him play a role in guiding EUSA’s commercial strategy for its cancer treatments.

Bryan Morton, executive chairman at EUSA Pharma, said: “Rolf’s strategic insight and guidance, based on significant commercial experience in the oncology field will prove invaluable as EUSA launches Qarziba and Fotivda in Europe.”

8th March 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics